The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021
May 24, 2021
Megan Wallace, DrPH; Kate R. Woodworth, MD; Julia W. Gargano, PhD; Heather M. Scobie, PhD; Amy E. Blain, MPH; Danielle Moulia, MPH; Mary Chamberland, MD; Nicole Reisman, MPH; Stephen C. Hadler, MD; Jessica R. MacNeil, MPH; Doug Campos-Outcalt, MD; Rebecca L. Morgan, PhD; Matthew F. Daley, MD; José R. Romero, MD; H. Keipp Talbot, MD; Grace M. Lee, MD; Beth P. Bell, MD; Sara E. Oliver, MD.
Morbidity and Mortality Weekly Report (MMWR)
Wallace et al. published a report highlighting the Advisory Committee on Immunization Practices (ACIP) interim recommendation to approve the use of Pfizer-BioNTech COVID-19 Vaccine for adolescents ages 12-15. The ACIP conducted a systematic review of all available data regarding the benefits, harms, preferences and values of families of the COVID-19 vaccines. Additionally, this interim recommendation was largely influenced by evidence of a randomized double-blind, placebo-controlled Phase II/III clinical trial using the Pfizer-BioNTech COVID-19 vaccine conducted on 2,200 adolescents 12-15 years old. The results of the trial showed 100% efficacy in preventing symptoms, high immune response towards the SARS-CoV-2 infection, low frequency of serious adverse medical events, and no safety concerns were reported. Overall, the researchers emphasized that addressing COVID-19 among adolescents is critical to slowing and controlling transmission. In order to address health disparities and inequity among populations disproportionately impacted by COVID-19, collaboration and engagement is required at a community level and systems level.
Wallace M, Woodworth KR, Gargano JW, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021. MMWR Morb Mortal Wkly Rep 2021. DOI:10.15585/mmwr.mm7020e1.